Hansson Lennart
Business Unit Manager Life Science @ Industrifonden
Hansson Lennart is a funding round investor at Industrifonden focused on Medical and Biopharma. Lennart has post-doctoral and research in molecular genetics at the University of Umeå worked in the pharmaceutical industry for about 20 years in various management positions in both large and small companies; KabiGen, AstraZeneca, Symbicom, Arexis and Biovitrum. As CEO of Arexis 2001-05 deepened the network of contacts and experience frominternational venture capital industry since 2006 Lennart has worked with investment in the life sciences industry in areas such Karolinska Development and from 2008 at the Industrial Development Fund as Head of Life Science business area.Lennart has worked in about 30 different boards and sits today in eg Pharma Link, Index Pharmaceuticals, Medtentia, Uminova Invest, Lund Bioscience and CMC Contrast. In addition, he participates in the Vancouver-based investment company Beacon PE.Spare time is devoted to nature, art and gardening.
- Total investments:
- 2
- Last investment:
- Lead investor:
- 0%
Last updated:
For AI agents: llms.txt
Industries Hansson Lennart invests in
Stages Hansson Lennart invests in
Countries Hansson Lennart invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Medical 1 (50%)
- Biopharma 1 (50%)
- Biotechnology 1 (50%)
Stage
- Funding Round 1 (50%)
- Private Equity 1 (50%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| InDex Pharmaceuticals AB is a clinical stage biopharmaceutical company building a leading immunotherapy franchise based on its TLR platform (toll-like receptors). It discovers and develops DIMS drugs (DNA-based immunomodulatory sequence) to treat diseases within a variety of therapeutic areas, including inflammation and cancer. | $20M / Feb 25, 2014 | ||
| InDex Pharmaceuticals AB is a clinical stage biopharmaceutical company building a leading immunotherapy franchise based on its TLR platform (toll-like receptors). It discovers and develops DIMS drugs (DNA-based immunomodulatory sequence) to treat diseases within a variety of therapeutic areas, including inflammation and cancer. | $7.2M / Private Equity / Jan 21, 2011 |
Co-Investors
About Industrifonden
Industrifonden is a Nordic evergreen venture capital firm with a fund size of $600m, that focuses on early-stage technology and life science companies with international potential. The company works long term with the entrepreneurs we invest in, and have a strong track record of building game changing companies. Industrifonden-backed companiesinclude tech companies Qlik, Arcam, Soundtrack Your Brand, Fishbrain, and life science companies CellaVision, Oncopeptides and AMRA.
Industrifonden Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Anna Ljungdahl
Investment Manager
|
|||
Bita Sehat
Investment Manager of Life Science
|
|||
Hadar Cars
Senior Investment Director
|
|||
|
Hansson Lennart
Business Unit Manager Life Science
|
|||
Jonas Jendi
Investment Director
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
FAQ
What does Hansson Lennart invest in?
Hansson Lennart invests primarily in Medical, Biopharma and Biotechnology startups, most often at Funding Round and Private Equity stage. Most of the 2 investments tracked by Shizune back companies in Sweden. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Hansson Lennart?
For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Hansson Lennart last invest?
The most recent investment recorded for Hansson Lennart closed in Feb 2014. Shizune tracks 2 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
